Products for Research Use Only
RegisterLogin

(S) -10-Hydroxycamptothecin-d5

CAT: 0804-HY-N0095S-01Size: 1 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-N0095S-01Size:1 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
(S) -10-Hydroxycamptothecin-d5 (10-HCPT-d5) is the deuterium labeled (S) -10-Hydroxycamptothecin. (S) -10-Hydroxycamptothecin (10-HCPT) is a DNA topoisomerase I inhibitor. (S) -10-Hydroxycamptothecin exhibits a remarkable apoptosis-inducing effect. (S) -10-Hydroxycamptothecin has the potential for hepatoma, gastric carcinoma, colon cancer and leukaemia research[1][2][3][4].
CAS Number
1330277-66-1
Product Name Alternative
10-HCPT-d5; 10-Hydroxycamptothecin-d5
UNSPSC
12352005
Target
Apoptosis; Isotope-Labeled Compounds; Topoisomerase
Related Pathways
Apoptosis; Cell Cycle/DNA Damage; Others
Applications
Cancer-programmed cell death
Field of Research
Cancer
Solubility
10 mM in DMSO
Smiles
O=C1N2C(C=3C(C2)=CC=4C(N3)=CC=C(O)C4)=CC5=C1COC(=O)[C@@]5(C(C([2H])([2H])[2H])([2H])[2H])O
Molecular Formula
C20H11D5N2O5
Molecular Weight
369.38
References & Citations
[1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53 (2) :211-216.|[2]Min Liu, et al. Intracellular delivery of 10-hydroxycamptothecin with targeted nanostructured lipid carriers against multidrug resistance . Journal of Drug Targeting.|[3]Min Liu, et al. Intracellular delivery of 10-hydroxycamptothecin with targeted nanostructured lipid carriers against multidrug resistance. J Drug Target, Early Online: 1–8|[4]Yu P, et al. Synthesis and preliminary anticancer evaluation of 10-hydroxycamptothecin analogs. Biol Pharm Bull. 2012;35 (8) :1295-9.|[5]Zhang XW, et al. Differentiation-inducing action of 10-hydroxycamptothecin on human hepatoma Hep G2 cells. Acta Pharmacol Sin. 2000 Apr;21 (4) :364-8.|[6]Zhang XW, et al. Differential regulation of P53, c-Myc, Bcl-2, Bax and AFP protein expression, and caspase activity during 10-hydroxycamptothecin-induced apoptosis in Hep G2 cells. Anticancer Drugs. 2000 Oct;11 (9) :747-56.|[7]Liu M, et al. Intracellular delivery of 10-hydroxycamptothecin with targeted nanostructured lipid carriers against multidrug resistance. J Drug Target. 2016;24 (5) :433-40.
Shipping Conditions
Room temperature
Scientific Category
Isotope-Labeled Compounds
Clinical Information
No Development Reported

Related Products

CatalogName
HY-N0095-01(S) -10-Hydroxycamptothecin
HY-N0095R-01(S) -10-Hydroxycamptothecin (Standard)
HY-N0275-01(±) -10-Hydroxycamptothecin
HY-N0275R(±) -10-Hydroxycamptothecin (Standard)
HY-W665464(Rac) -7-Ethyl-10-hydroxycamptothecin
HY-N05729-Hydroxycamptothecin
HY-133171AS-01(S) -Norfluoxetine-d5 (phenyl-d5)
HY-109854S(S) -Lisofylline-d5
HY-130239S14 (S) -HDHA-d5
HY-130675AS-0115 (S) -HEPE-d5

Alternative Products

CatalogName
CS-O-031477-Ethyl-10-Hydroxycamptothecin-d5 (SN 38-d5)
GTR19175337-01(±) -10-Hydroxycamptothecin
N2591-2010-Hydroxycamptothecin
TB0033-100010-Hydroxycamptothecin(e)
BUP13827-01(S) -10-Hydroxycamptothecin
B4745-100(S)-10-Hydroxycamptothecin

Popular Products